Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL930669 | 0.89 | L3MBTL1 (0.57) | TDP1GAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL931150 | 0.86 | TDP1 (0.52) | TDP1GAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL930959 | 0.79 | TDP1 (0.58) | TDP1GAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL13527490 | 0.75 | RAB9A (0.56) | TDP1GAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL931076 | 0.75 | TDP1 (0.61) | TDP1GAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL14501101 | 0.75 | ALDH1A1 (0.56) | TDP1GAASMN1; SMN2KMT2AL3MBTL1 | |
| SCHEMBL16109895 | 0.74 | ALDH1A1 (0.67) | TDP1SMN1; SMN2MEN1KMT2ARAB9A | |
| SCHEMBL3533267 | 0.73 | LMNA (0.62) | SMN1; SMN2MEN1KMT2ARAB9AL3MBTL1 | |
| SCHEMBL5637576 | 0.70 | PKM (0.50) | TDP1GAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL64640 | 0.70 | MAPK1 (0.65) | TDP1GAASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875615-B2 | 3-(4-Fluoro-2-methyl-phenyl)-6-[5-methoxymethyl-4-(6-methoxy-pyridin-3-yl)-4H-[1,2,4]triazol-3-yl]-pyridazine; treatment of male sexual dysfunction, female sexual dysfunction, hypoactive sexual desire disorder, sexual arousal disorder, orgasmic disorder, sexual pain disorder, or premature ejaculation | PFIZER INC (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875615-B2 | 3-(4-Fluoro-2-methyl-phenyl)-6-[5-methoxymethyl-4-(6-methoxy-pyridin-3-yl)-4H-[1,2,4]triazol-3-yl]-pyridazine; treatment of male sexual dysfunction, female sexual dysfunction, hypoactive sexual desire disorder, sexual arousal disorder, orgasmic disorder, sexual pain disorder, or premature ejaculation | PFIZER INC (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875615-B2 | 3-(4-Fluoro-2-methyl-phenyl)-6-[5-methoxymethyl-4-(6-methoxy-pyridin-3-yl)-4H-[1,2,4]triazol-3-yl]-pyridazine; treatment of male sexual dysfunction, female sexual dysfunction, hypoactive sexual desire disorder, sexual arousal disorder, orgasmic disorder, sexual pain disorder, or premature ejaculation | PFIZER INC (US) | 2011-01-25 | — | — | US | disclosed |
| US-20100063064-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | PFIZER INC | 2010-03-11 | — | — | US | disclosed |
| US-20100063064-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | PFIZER INC | 2010-03-11 | — | — | US | disclosed |
| US-20100063064-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | PFIZER INC | 2010-03-11 | — | — | US | disclosed |
| US-7649003-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7649003-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7649003-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20080108625-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | PFIZER INC | 2008-05-08 | — | — | US | disclosed |
| US-20080108625-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | PFIZER INC | 2008-05-08 | — | — | US | disclosed |
| US-20080108625-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | PFIZER INC | 2008-05-08 | — | — | US | disclosed |
| US-7291640-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291640-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291640-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2007-11-06 | — | — | US | disclosed |
| WO-2005028452-A9 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LTD (GB) | 2005-07-21 | — | — | WO | disclosed |
| US-20050107382-A1 | e.g. 2-(4-fluoro-2-methylphenyl)-5-(5-methoxymethyl-4-(6-methoxypyridin-3-yl)-4H-[1,2,4]triazol-3-yl)-pyridine; treatment of arousal disorder, orgasmic disorder, sexual pain disorder and premature ejaculation, preterm labor, appetite and feeding disorders, dysmenorrhoea, congestive heart failure, etc. | PFIZER INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063064-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | OXTR, PRLHR, KISS1R | TDP1 375/4885GAA 4379/4885SMN1; SMN2 2465/4885 |
| US-20050107382-A1 | e.g. 2-(4-fluoro-2-methylphenyl)-5-(5-methoxymethyl-4-(6-methoxypyridin-3-yl)-4H-[1,2,4]triazol-3-yl)-pyridine; treatment of arousal disorder, orgasmic disorder, sexual pain disorder and premature ejaculation, preterm labor, appetite and feeding disorders, dysmenorrhoea, congestive heart failure, etc. | OXTR, OPRL1, NPY4R | TDP1 1444/4885GAA 3939/4885SMN1; SMN2 1147/4885 |
| US-20080108625-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | OXTR, PRLHR, KISS1R | TDP1 375/4885GAA 4379/4885SMN1; SMN2 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.